About: Rivastigmine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rivastigmine Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B4A84-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4A85-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4A86-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4A87-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4A88-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4A89-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4A8A-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4A8B-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4A8C-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4A8D-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Camps P, Munoz-Torrero D: Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Rev Med Chem. 2002 Feb;2(1):11-25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12369954 # Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999 Mar 6;318(7184):633-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10066203 # Finkel SI: Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin Ther. 2004 Jul;26(7):980-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15336465 # Rosler M, Retz W, Retz-Junginger P, Dennler HJ: Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol. 1998;11(4):211-216. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11568422 # Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2509-18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15590953 # Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE: Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19370562# Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J: Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009;12(1):79-85. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19470293 # Farlow MR: Update on rivastigmine. Neurologist. 2003 Sep;9(5):230-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14587496 (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	1.5 hours (en)
http://linked.open...ugbank/indication	For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type. (en)
http://linked.open...bank/manufacturer	Able laboratories inc American therapeutics inc Primedics Laboratories Baxter healthcare corp
sameAs	Rivastigmine
Title	Rivastigmine (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB00989/identifier/bindingdb/10620 http://linked.opendata.cz/resource/drugbank/drug/DB00989/identifier/chemspider/70377 http://linked.opendata.cz/resource/drugbank/drug/DB00989/identifier/drugbank/DB00989 http://linked.opendata.cz/resource/drugbank/drug/DB00989/identifier/kegg-compound/C11766 http://linked.opendata.cz/resource/drugbank/drug/DB00989/identifier/kegg-drug/D03822 http://linked.opendata.cz/resource/drugbank/drug/DB00989/identifier/national-drug-code-directory/0078-0501-15 http://linked.opendata.cz/resource/drugbank/drug/DB00989/identifier/pharmgkb/PA451262 http://linked.opendata.cz/resource/drugbank/drug/DB00989/identifier/pubchem-compound/77991 http://linked.opendata.cz/resource/drugbank/drug/DB00989/identifier/pubchem-substance/46507452 http://linked.opendata.cz/resource/drugbank/drug/DB00989/identifier/wikipedia/Rivastigmine
http://linked.open...mechanismOfAction	Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues. (en)
http://linked.open...drugbank/packager	Baxter healthcare corp anesthesia and critical care Bedford Labs Ben Venue Laboratories Inc. Cardinal Health APP Pharmaceuticals APPD Bedford Labs Astrazeneca lp Sandoz Baxter healthcare corp anesthesia critical care Abraxis pharmaceutical products App pharmaceuticals llc
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/2315784 http://linked.opendata.cz/resource/drugbank/patent/4948807 http://linked.opendata.cz/resource/drugbank/patent/6316023
http://linked.open...outeOfElimination	Rivastigmine is extensively metabolized primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite NAP226-90. Renal excretion of the metabolites is the major route of elimination. Less than 1% of the administered dose is excreted in the feces. (en)
http://linked.open.../drugbank/synonym	Ena 713 Free Base (en) (S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate (en) m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate (en)
http://linked.open...umeOfDistribution	* 1.8 to 2.7 L/kg (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/12-04-00
http://linked.open...nk/proteinBinding	40% (en)
http://linked.open...ynthesisReference	Venkata Naga Brahmeswara Rao Mandava, Venkata Reddy Vajrala, Ganesh Varanasi, Vijay Kumar Adla, Mukund Reddy Jambula, Vijaypal Reddy Kanumathi Reddy, "PREPARATION OF RIVASTIGMINE AND ITS SALTS." U.S. Patent US20080255383, issued October 16, 2008. (en)
foaf:page	http://www.drugs.com/cdi/rivastigmine.html http://www.rxlist.com/cgi/generic2/rivastig.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4A92-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B4A98-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B4A97-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4A94-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4A95-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B4A96-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B4A90-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B4A8E-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B4A91-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B4AA7-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B4A8F-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Rivastigmine
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4A9E-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4A9F-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B4A99-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B4A9A-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B4A9C-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B4A9B-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B4A9D-363D-11E5-9242-09173F13E4C5
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	123441-03-2 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	* renal cl=2.1-2.8 L/hr (en)
http://linked.open...gbank/containedIn	Exelon 1.5 mg capsule Dobutamine 250 mg-d5w 500 ml Dobutamine 12.5 mg/ml vial Exelon 6 mg capsule Exelon 4.6 mg/24hr patch Exelon 9.5 mg/24hr patch Exelon 30 4.6 mg/24hr Patches Box Exelon 30 9.5 mg/24hr Patches Box
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B4AA3-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B4AA5-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B4AA6-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B4AA2-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B4AA1-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B4AA4-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4A93-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B4AA0-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 39 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software